Poor
Not Aligned
Patient Risk:
Low
Summary
The claims are about a savings/copay/trial program and generic pricing/competition. The provided FDA prescribing information excerpts do not include any information supporting or contradicting such access, eligibility, activation methods, caps, exclusions, or cost statements; therefore most claims are unsupported/absent from the supplied label content.
Category Scores
Accurate Statements
Unsupported Statements
Vascepa (icosapent ethyl) loyalty members can access copay assistance through the Vascepa Savings Card program managed by Amarin Pharma.
No label excerpt provided addresses copay assistance/loyalty programs, managing entities, or patient access mechanisms.
The copay assistance can reduce out-of-pocket costs to as low as $9 per 90-day prescription fill for eligible commercially insured patients.
No label excerpt provided includes patient copay amounts, cost reduction guarantees, or thresholds by fill duration.
There is a maximum savings cap of $11,700 per year per patient.
No label excerpt provided includes annual savings caps.
The savings card program requires no enrollment beyond activating the card online or by phone.
No label excerpt provided describes any activation/enrollment requirements for a savings card.
Eligibility requires commercial insurance and a valid prescription.
No label excerpt provided describes eligibility criteria for any copay assistance program.
The program excludes government insurance programs such as Medicare and Medicaid.
No label excerpt provided describes insurance-type exclusions for any assistance program.
Patients can activate the card via VascepaSupport.com, by texting "START" to 91830, or by calling 1-844-726-8008.
No label excerpt provided lists activation websites, texting keywords/short codes, or telephone numbers.
The savings card can be digital or printable and is processed at pharmacy checkout.
No label excerpt provided describes format (digital/printable) or point-of-sale processing mechanics for a savings card.
Uninsured patients pay the full cash price (around $300–$400 monthly without discounts).
No label excerpt provided includes pricing information for uninsured patients.
The program does not cover uninsured patients directly.
No label excerpt provided describes whether uninsured patients are covered by any assistance program.
A free trial offer provides up to three 30-day supplies for new patients.
No label excerpt provided includes any free trial offer terms or supply limits.
The free trial is available via doctor offices or pharmacies.
No label excerpt provided includes trial distribution channels.
As of 2023, Amarin extended the savings card amid generic competition from Hikma Pharmaceuticals launched October 2023.
No label excerpt provided includes corporate program updates or timing related to generic competition.
The offer remains active but excludes states with mandatory generic substitution laws such as California.
No label excerpt provided includes state-specific exclusions tied to generic substitution laws.
Generics of icosapent ethyl are available at lower costs (~$20–$50 monthly).
No label excerpt provided includes generic availability or pricing ranges.
Contradictions
Important Omissions
Any FDA-label-supported description of contraindications/warnings/dosage/administration for the specific claims context (e.g., safety, eligible populations) corresponding to the savings/pricing assertions.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The provided AI claims are primarily administrative (copay assistance, activation steps, pricing, eligibility exclusions) and do not make direct safety claims about VASCEPA dosing or risks. However, because these claims are unsupported by the supplied FDA label excerpts, there is potential risk of misinformation about access/cost, which could indirectly affect treatment decisions.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most claims are not supported or addressed in the provided FDA-approved prescribing information excerpts (they describe copay/trial/program mechanics and pricing/eligibility details not present in Sections 1, 2, 4-8, 12, or 14).
Suggested Improvement
Limit the response to FDA-label content provided (indications, dosing instructions, contraindications, warnings/precautions, adverse reactions, interactions, and labeled populations). For savings-card/program details, cite the specific program terms (not included in the provided label excerpts) rather than implying FDA-label support.